Also, in my capacity as Lead Independent Director, I have talked to many shareholders about their thoughts and opinions. Given the importance of exenatide once weekly, many shareholders expressed an interest in having more operational and commercial expertise on the Board. I would like to extend sincere appreciation on behalf of the entire Board for the time our shareholders spent with us, and the thoughtfulness and candor that they brought to these conversations. We look forward to continuing this very important dialogue.
The result of our detailed review process and the extensive feedback we received is the nomination of a slate of highly qualified individuals. We are confident that our slate of 12 nominees is best positioned to serve the interests of all our shareholders. The two new independent nominees to our Board are Paul N. Clark, former Chairman, Chief Executive Officer and President of Icos Corporation, and Paulo F. Costa, former President and Chief Executive Officer of Novartis U.S. Corporation. Both possess valuable commercial and operational expertise in the biopharmaceutical industry, enhancing the existing strengths of the Board, and both are widely respected leaders who we look forward to having on the Amylin team.
In addition to the new nominees, the company is nominating current directors Adrian Adams, Steven R. Altman, Teresa Beck, Daniel M. Bradbury, Joseph C. Cook, Jr., Karin Eastham, James R. Gavin III, M.D., Ph.D., Jay S. Skyler, M.D., Joseph P. Sullivan and me for re-election. These directors have an in-depth k
|SOURCE Amylin Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved